Search for "C(sp3)–H bond functionalization" in Full Text gives 8 result(s) in Beilstein Journal of Organic Chemistry.
Beilstein J. Org. Chem. 2021, 17, 1849–1938, doi:10.3762/bjoc.17.126
Graphical Abstract
Scheme 1: Schematic overview of transition metals studied in C–H activation processes.
Scheme 2: (A) Known biological activities related to benzimidazole-based compounds; (B and C) an example of a...
Scheme 3: (A) Known biological activities related to quinoline-based compounds; (B and C) an example of a sca...
Scheme 4: (A) Known biological activities related to sulfur-containing compounds; (B and C) an example of a s...
Scheme 5: (A) Known biological activities related to aminoindane derivatives; (B and C) an example of a scand...
Scheme 6: (A) Known biological activities related to norbornane derivatives; (B and C) an example of a scandi...
Scheme 7: (A) Known biological activities related to aniline derivatives; (B and C) an example of a titanium-...
Scheme 8: (A) Known biological activities related to cyclohexylamine derivatives; (B) an example of an intram...
Scheme 9: (A) Known biologically active benzophenone derivatives; (B and C) photocatalytic oxidation of benzy...
Scheme 10: (A) Known bioactive fluorine-containing compounds; (B and C) vanadium-mediated C(sp3)–H fluorinatio...
Scheme 11: (A) Known biologically active Lythraceae alkaloids; (B) synthesis of (±)-decinine (30).
Scheme 12: (A) Synthesis of (R)- and (S)-boehmeriasin (31); (B) synthesis of phenanthroindolizidines by vanadi...
Scheme 13: (A) Known bioactive BINOL derivatives; (B and C) vanadium-mediated oxidative coupling of 2-naphthol...
Scheme 14: (A) Known antiplasmodial imidazopyridazines; (B) practical synthesis of 41.
Scheme 15: (A) Gold-catalyzed drug-release mechanism using 2-alkynylbenzamides; (B and C) chromium-mediated al...
Scheme 16: (A) Examples of anti-inflammatory benzaldehyde derivatives; (B and C) chromium-mediated difunctiona...
Scheme 17: (A and B) Manganese-catalyzed chemoselective intramolecular C(sp3)–H amination; (C) late-stage modi...
Scheme 18: (A and B) Manganese-catalyzed C(sp3)–H amination; (C) late-stage modification of a leelamine deriva...
Scheme 19: (A) Known bioactive compounds containing substituted N-heterocycles; (B and C) manganese-catalyzed ...
Scheme 20: (A) Known indoles that present GPR40 full agonist activity; (B and C) manganese-catalyzed C–H alkyl...
Scheme 21: (A) Examples of known biaryl-containing drugs; (B and C) manganese-catalyzed C–H arylation through ...
Scheme 22: (A) Known zidovudine derivatives with potent anti-HIV properties; (B and C) manganese-catalyzed C–H...
Scheme 23: (A and B) Manganese-catalyzed C–H organic photo-electrosynthesis; (C) late-stage modification.
Scheme 24: (A) Example of a known antibacterial silylated dendrimer; (B and C) manganese-catalyzed C–H silylat...
Scheme 25: (A and B) Fe-based small molecule catalyst applied for selective aliphatic C–H oxidations; (C) late...
Scheme 26: (A) Examples of naturally occurring gracilioethers; (B) the first total synthesis of gracilioether ...
Scheme 27: (A and B) Selective aliphatic C–H oxidation of amino acids; (C) late-stage modification of proline-...
Scheme 28: (A) Examples of Illicium sesquiterpenes; (B) first chemical synthesis of (+)-pseudoanisatin (80) in...
Scheme 29: (A and B) Fe-catalyzed deuteration; (C) late-stage modification of pharmaceuticals.
Scheme 30: (A and B) Biomimetic Fe-catalyzed aerobic oxidation of methylarenes to benzaldehydes (PMHS, polymet...
Scheme 31: (A) Known tetrahydroquinolines with potential biological activities; (B and C) redox-selective Fe c...
Scheme 32: (A) Known drugs containing a benzofuran unit; (B and C) Fe/Cu-catalyzed tandem O-arylation to acces...
Scheme 33: (A) Known azaindolines that act as M4 muscarinic acetylcholine receptor agonists; (B and C) intramo...
Scheme 34: (A) Known indolinones with anticholinesterase activity; (B and C) oxidative C(sp3)–H cross coupling...
Scheme 35: (A and B) Cobalt-catalyzed C–H alkenylation of C-3-peptide-containing indoles; (C) derivatization b...
Scheme 36: (A) Cobalt-Cp*-catalyzed C–H methylation of known drugs; (B and C) scope of the o-methylated deriva...
Scheme 37: (A) Known lasalocid A analogues; (B and C) three-component cobalt-catalyzed C–H bond addition; (D) ...
Scheme 38: (A and B) Cobalt-catalyzed C(sp2)–H amidation of thiostrepton.
Scheme 39: (A) Known 4H-benzo[d][1,3]oxazin-4-one derivatives with hypolipidemic activity; (B and C) cobalt-ca...
Scheme 40: (A and B) Cobalt-catalyzed C–H arylation of pyrrole derivatives; (C) application for the synthesis ...
Scheme 41: (A) Known 2-phenoxypyridine derivatives with potent herbicidal activity; (B and C) cobalt-catalyzed...
Scheme 42: (A) Natural cinnamic acid derivatives; (B and C) cobalt-catalyzed C–H carboxylation of terminal alk...
Scheme 43: (A and B) Cobalt-catalyzed C–H borylation; (C) application to the synthesis of flurbiprofen.
Scheme 44: (A) Benzothiazoles known to present anticonvulsant activities; (B and C) cobalt/ruthenium-catalyzed...
Scheme 45: (A and B) Cobalt-catalyzed oxygenation of methylene groups towards ketone synthesis; (C) synthesis ...
Scheme 46: (A) Known anticancer tetralone derivatives; (B and C) cobalt-catalyzed C–H difluoroalkylation of ar...
Scheme 47: (A and B) Cobalt-catalyzed C–H thiolation; (C) application in the synthesis of quetiapine (153).
Scheme 48: (A) Known benzoxazole derivatives with anticancer, antifungal, and antibacterial activities; (B and...
Scheme 49: (A and B) Cobalt-catalyzed C–H carbonylation of naphthylamides; (C) BET inhibitors 158 and 159 tota...
Scheme 50: (A) Known bioactive pyrrolo[1,2-a]quinoxalin-4(5H)-one derivatives; (B and C) cobalt-catalyzed C–H ...
Scheme 51: (A) Known antibacterial cyclic sulfonamides; (B and C) cobalt-catalyzed C–H amination of propargyli...
Scheme 52: (A and B) Cobalt-catalyzed intramolecular 1,5-C(sp3)–H amination; (C) late-stage functionalization ...
Scheme 53: (A and B) Cobalt-catalyzed C–H/C–H cross-coupling between benzamides and oximes; (C) late-state syn...
Scheme 54: (A) Known anticancer natural isoquinoline derivatives; (B and C) cobalt-catalyzed C(sp2)–H annulati...
Scheme 55: (A) Enantioselective intramolecular nickel-catalyzed C–H activation; (B) bioactive obtained motifs;...
Scheme 56: (A and B) Nickel-catalyzed α-C(sp3)–H arylation of ketones; (C) application of the method using kno...
Scheme 57: (A and B) Nickel-catalyzed C(sp3)–H acylation of pyrrolidine derivatives; (C) exploring the use of ...
Scheme 58: (A) Nickel-catalyzed C(sp3)–H arylation of dioxolane; (B) library of products obtained from biologi...
Scheme 59: (A) Intramolecular enantioselective nickel-catalyzed C–H cycloalkylation; (B) product examples, inc...
Scheme 60: (A and B) Nickel-catalyzed C–H deoxy-arylation of azole derivatives; (C) late-stage functionalizati...
Scheme 61: (A and B) Nickel-catalyzed decarbonylative C–H arylation of azole derivatives; (C) application of t...
Scheme 62: (A and B) Another important example of nickel-catalyzed C–H arylation of azole derivatives; (C) app...
Scheme 63: (A and B) Another notable example of a nickel-catalyzed C–H arylation of azole derivatives; (C) lat...
Scheme 64: (A and B) Nickel-based metalorganic framework (MOF-74-Ni)-catalyzed C–H arylation of azole derivati...
Scheme 65: (A) Known commercially available benzothiophene-based drugs; (B and C) nickel-catalyzed C–H arylati...
Scheme 66: (A) Known natural tetrahydrofuran-containing substances; (B and C) nickel-catalyzed photoredox C(sp3...
Scheme 67: (A and B) Another notable example of a nickel-catalyzed photoredox C(sp3)–H alkylation/arylation; (...
Scheme 68: (A) Electrochemical/nickel-catalyzed C–H alkoxylation; (B) achieved scope, including three using na...
Scheme 69: (A) Enantioselective photoredox/nickel catalyzed C(sp3)–H arylation; (B) achieved scope, including ...
Scheme 70: (A) Known commercially available trifluoromethylated drugs; (B and C) nickel-catalyzed C–H trifluor...
Scheme 71: (A and B) Stereoselective nickel-catalyzed C–H difluoroalkylation; (C) late-stage functionalization...
Scheme 72: (A) Cu-mediated ortho-amination of oxalamides; (B) achieved scope, including derivatives obtained f...
Scheme 73: (A) Electro-oxidative copper-mediated amination of 8-aminoquinoline-derived amides; (B) achieved sc...
Scheme 74: (A and B) Cu(I)-mediated C–H amination with oximes; (C) derivatization using telmisartan (241) as s...
Scheme 75: (A and B) Cu-mediated amination of aryl amides using ammonia; (C) late-stage modification of proben...
Scheme 76: (A and B) Synthesis of purine nucleoside analogues using copper-mediated C(sp2)–H activation.
Scheme 77: (A) Copper-mediated annulation of acrylamide; (B) achieved scope, including the synthesis of the co...
Scheme 78: (A) Known bioactive compounds containing a naphthyl aryl ether motif; (B and C) copper-mediated eth...
Scheme 79: (A and B) Cu-mediated alkylation of N-oxide-heteroarenes; (C) late-stage modification.
Scheme 80: (A) Cu-mediated cross-dehydrogenative coupling of polyfluoroarenes and alkanes; (B) scope from know...
Scheme 81: (A) Known anticancer acrylonitrile compounds; (B and C) Copper-mediated cyanation of unactivated al...
Scheme 82: (A) Cu-mediated radiofluorination of 8-aminoquinoline-derived aryl amides; (B) achieved scope, incl...
Scheme 83: (A) Examples of natural β-carbolines; (B and C) an example of a zinc-catalyzed C–H functionalizatio...
Scheme 84: (A) Examples of anticancer α-aminophosphonic acid derivatives; (B and C) an example of a zinc-catal...
Beilstein J. Org. Chem. 2020, 16, 3093–3103, doi:10.3762/bjoc.16.259
Graphical Abstract
Scheme 1: Benzylic addition of aldehydes to azaarenes using different catalysts.
Scheme 2: Synthesis of azaarene derivatives from different precursors.
Scheme 3: Our work: catalyst- and solvent-free benzylic addition of aldehydes to azaarenes.
Scheme 4: Large-scale experiments for the synthesis of 2-(6-methylpyridin-2-yl)-1-(4-nitrophenyl)ethan-1-ol (...
Scheme 5: Plausible mechanism for the formation of 2-(6-methylpyridin-2-yl)-1-(4-nitrophenyl)ethan-1-ol (3a) ...
Beilstein J. Org. Chem. 2020, 16, 833–857, doi:10.3762/bjoc.16.76
Graphical Abstract
Scheme 1: Norrish type I and II dissociations.
Scheme 2: Proposed radical pair formation after the photolysis of benzaldehyde (8).
Scheme 3: Aldehydes in the Paterno–Büchi reaction.
Scheme 4: 2,3-Diazabicyclo[2.2.1]hept-2-ene (DBH).
Scheme 5: Dissociation pathways of benzaldehyde.
Scheme 6: Reactions that lead to polarized products detectable by CIDNP.
Scheme 7: MMA (26), DEABP (27), and Michler’s ketone (28).
Scheme 8: Radical intermediates of DEABP.
Scheme 9: Photoinitiated polymerization of monomeric MMA (26) using the quinoxalines 32 and benzaldehyde (8).
Scheme 10: Acetone (4) and formaldehyde (35) as photografting initiators.
Scheme 11: Photografting by employing acetaldehyde (36) as the photoinitiator.
Scheme 12: Proposed photolysis mechanism for aliphatic ketones 44 and formaldehyde (35).
Scheme 13: Initiator 50, reductant 51, and benzaldehyde derivatives 52–54 for the polymerization of the methac...
Scheme 14: Proposed mechanism of the photomediated atom transfer radical polymerization employing the benzalde...
Scheme 15: cis/trans isomerization employing triplet states of photosensitizers.
Scheme 16: Salicylaldehyde (68) forms an internal hydrogen bond.
Scheme 17: Olefin isomerization via energy transfer from a carbonyl compound.
Scheme 18: Mechanistic pathways for the Paterno–Büchi reaction.
Scheme 19: Isomeric oxetanes formed after photochemical addition of aryl aldehydes to 2-butenes.
Scheme 20: Rotation of the C3–C4 bond of the biradical intermediate may lead to all four conformations.
Scheme 21: Photolysis products of benzaldehyde (8) in different solvents. a) In benzene or ethanol. b) In hex-...
Scheme 22: N-tert-Butylbenzamide formation proceeds via a benzoyl radical.
Scheme 23: Photochemical pinacol coupling.
Scheme 24: Photochemical ATRA catalyzed by 4-anisaldehyde (52).
Scheme 25: Proposed triplet sensitization mechanism of the ATRA reaction in the presence of 4-anisaldehyde (52...
Scheme 26: Benzaldehyde-mediated photoredox CDC reaction: compatible amides and ethers.
Scheme 27: Photoredox cross-dehydrogenative coupling (CDC) conditions and proposed reaction mechanism.
Scheme 28: Optimized conditions for the photoredox merger reaction.
Scheme 29: Proposed mechanism for the C(sp3)–H alkylation/arylation of ethers.
Scheme 30: Substrate scope for the photochemical alkylation of ethers.
Scheme 31: C(sp3)–H Functionalization of N-containing molecules.
Scheme 32: Substrate scope for the photochemical alkylation of N-containing molecules.
Scheme 33: Additional products yielded by the photochemical alkylation reaction of N-containing molecules.
Scheme 34: C(sp3)–H functionalization of thioethers.
Scheme 35: Proposed mechanism for the C(sp3)–H alkylation/arylation of N-containing molecules and thioethers.
Scheme 36: Hydroacylation using 4-cyanobenzaldehyde (53) as the photoinitiator.
Scheme 37: Selectivity for the formation of the α,α-disubstituted aldehydes.
Scheme 38: Substrate scope for the photochemical addition of aldehydes to Michael acceptors.
Scheme 39: Proposed mechanism for the hydroacylation of Michael acceptors using 4-cyanobenzaldehyde (53) as th...
Scheme 40: Catalytic arylation of aromatic aldehydes by aryl bromides in which the reaction product acts as th...
Scheme 41: Proposed mechanism for the catalytic arylation of benzaldehydes by aryl bromides in which the react...
Scheme 42: Functionalization of the chiral cyclobutanes 180.
Scheme 43: Optimized reaction conditions and proposed mechanism for the sulfonylcyanation of cyclobutenes.
Beilstein J. Org. Chem. 2017, 13, 1670–1692, doi:10.3762/bjoc.13.162
Graphical Abstract
Figure 1: Representative bioactive heterocycles.
Scheme 1: The concept of oxidative dehydrogenation.
Scheme 2: IBX-mediated oxidative dehydrogenation of various heterocycles [31-34].
Scheme 3: Potential mechanism of IBX-mediated oxidative dehydrogenation of N-heterocycles [31-34].
Scheme 4: IBX-mediated room temperature one-pot condensation–oxidative dehydrogenation of o-aminobenzylamines....
Scheme 5: Anhydrous cerium chloride-catalyzed, IBX-mediated oxidative dehydrogenation of various heterocycles...
Scheme 6: Oxidative dehydrogenation of quinazolinones with I2 and DDQ [37-40].
Scheme 7: DDQ-mediated oxidative dehydrogenation of thiazolidines and oxazolidines.
Scheme 8: Oxone-mediated oxidative dehydrogenation of intermediates from o-phenylenediamine and o-aminobenzyl...
Scheme 9: Transition metal-free oxidative cross-dehydrogenative coupling.
Scheme 10: NaOCl-mediated oxidative dehydrogenation.
Scheme 11: NBS-mediated oxidative dehydrogenation of tetrahydro-β-carbolines.
Scheme 12: One-pot synthesis of various methyl(hetero)arenes from o-aminobenzamide in presence of di-tert-buty...
Scheme 13: Oxidative dehydrogenation of 1, 4-DHPs.
Scheme 14: Synthesis of quinazolines in the presence of MnO2.
Scheme 15: Selenium dioxide and potassium dichromate-mediated oxidative dehydrogenation of tetrahydro-β-carbol...
Scheme 16: Synthesis of substituted benzazoles in the presence of barium permanganate.
Scheme 17: Oxidative dehydrogenation with phenanthroline-based catalysts. PPTS = pyridinium p-toluenesulfonic ...
Scheme 18: Oxidative dehydrogenation with Flavin mimics.
Scheme 19: o-Quinone based bioinspired catalysts for the synthesis of dihydroisoquinolines.
Scheme 20: Cobalt-catalyzed aerobic dehydrogenation of Hantzch 1,4-DHPs and pyrazolines.
Scheme 21: Mechanism of cobalt-catalyzed aerobic dehydrogenation of Hantzch 1,4-DHPs.
Scheme 22: DABCO and TEMPO-catalyzed aerobic oxidative dehydrogenation of quinazolines and 4H-3,1-benzoxazines....
Scheme 23: Putative mechanism for Cu(I)–DABCO–TEMPO catalyzed aerobic oxidative dehydrogenation of tetrahydroq...
Scheme 24: Potassium triphosphate modified Pd/C catalysts for the oxidative dehydrogenation of tetrahydroisoqu...
Scheme 25: Ruthenium-catalyzed polycyclic heteroarenes.
Scheme 26: Plausible mechanism of the ruthenium-catalyzed dehydrogenation.
Scheme 27: Bi-metallic platinum/iridium alloyed nanoclusters and 5,5’,6,6’-tetrahydroxy-3,3,3’,3’-tetramethyl-...
Scheme 28: Magnesium iodide-catalyzed synthesis of quinazolines.
Scheme 29: Ferrous chloride-catalyzed aerobic dehydrogenation of 1,2,3,4-tetrahydroquinolines.
Scheme 30: Cu(I)-catalyzed oxidative aromatization of indoles.
Scheme 31: Putative mechanism of the transformation.
Scheme 32: Oxidative dehydrogenation of pyrimidinones and pyrimidines.
Scheme 33: Putative mechanisms (radical and metal-catalyzed) of the transformation.
Scheme 34: Ferric chloride-catalyzed, TBHP-oxidized synthesis of substituted quinazolinones and arylquinazolin...
Scheme 35: Iridium-catalyzed oxidative dehydrogenation of quinolines.
Scheme 36: Microwave-assisted synthesis of β-carboline with a catalytic amount of Pd/C in lithium carbonate at...
Scheme 37: 4-Methoxy-TEMPO-catalyzed aerobic oxidative synthesis of 2-substituted benzazoles.
Scheme 38: Plausible mechanism of the 4-methoxy-TEMPO-catalyzed transformation.
Scheme 39: One-pot synthesis of 2-arylquinazolines, catalyzed by 4-hydroxy-TEMPO.
Scheme 40: Oxidative dehydrogenation – a key step in the synthesis of AZD8926.
Scheme 41: Catalytic oxidative dehydrogenation of tetrahydroquinolines to afford bioactive molecules.
Scheme 42: Iodobenzene diacetate-mediated synthesis of β-carboline natural products.
Beilstein J. Org. Chem. 2016, 12, 882–902, doi:10.3762/bjoc.12.87
Graphical Abstract
Figure 1: Singlet carbene, triplet carbene and carbenoids.
Figure 2: Classification of the carbenoid intermediates by the electronic nature of the groups attached to th...
Figure 3: Chiral bis(oxazoline) ligands used in enantioselective copper carbenoid insertion.
Scheme 1: Pioneering work of Peter Yates on the carbenoid insertion reaction into X–H bonds (where X = O, S, ...
Scheme 2: Copper carbenoid insertion into C(sp3)–H bond of a stereogenic center with full retention of the as...
Scheme 3: Carbenoid insertion into a C(sp3)–H bond as the key step of the Taber’s (+)-α-cuparenone (8) synthe...
Scheme 4: First enantioselective carbenoid insertion into C–O bonds catalyzed by chiral metallic complexes.
Figure 4: Chemical structures of complexes (R)-18 and (S)-18.
Scheme 5: Asymmetric carbenoid insertions into C(sp3)–H bonds of cycloalkanes catalyzed by chiral rhodium car...
Scheme 6: First diastereo and enantioselective intermolecular carbenoid insertion into tetrahydrofuran C(sp3)...
Scheme 7: Simplified mechanism of the carbenoid insertion into a C(sp3)–H bond.
Scheme 8: Nakamura’s carbenoid insertion into a C(sp3)–H bond catalytic cycle.
Scheme 9: Investigation of the relationship between the electronic characteristics of the substituent X attac...
Scheme 10: Empirical model to predict the stereoselectivity of the donor/acceptor dirhodium carbenoid insertio...
Scheme 11: Asymmetric insertion of copper carbenoids in C(sp3)–H bonds to prepare trans-γ-lactam.
Figure 5: Iridium catalysts used by Suematsu and Katsuki for carbenoid insertion into C(sp3)–H bonds.
Scheme 12: Chiral porphyrin iridium complex catalyzes the carbenoid insertion into bis-allylic C(sp3)–H bonds.
Scheme 13: Chiral porphyrin iridium complex catalyzes the carbenoid insertion into tetrahydrofuran C(sp3)–H bo...
Scheme 14: Chiral porphyrin–iridium complex catalyzes the intramolecular carbenoid insertion into C(sp3)–H bon...
Scheme 15: Chiral bis(oxazoline)–iridium complex catalyzes the carbenoid insertion into bis-allylic C(sp3)–H b...
Scheme 16: New cyclopropylcarboxylate-based chiral catalyst to enantioselective carbenoid insertion into the e...
Scheme 17: Regio- and enantioselective carbenoid insertion into the C(sp3)–H bond catalyzed by a new bulky cyc...
Scheme 18: Regio and diastereoselective carbenoid insertion into the C(sp3)–H bond catalyzed by a new bulky cy...
Scheme 19: 2,2,2-Trichloroethyl (TCE) aryldiazoacetates to improve the scope, regio- and enantioselective of t...
Scheme 20: Sequential C–H functionalization approach to 2,3-dihydrobenzofurans.
Scheme 21: Enantioselective intramolecular rhodium carbenoid insertion into C(sp3)–H bonds to afford cis-disub...
Scheme 22: Enantioselective intramolecular rhodium carbenoid insertion into C(sp3)–H bonds to afford cis-2-vin...
Scheme 23: First rhodium porphyrin-based catalyst for enantioselective carbenoid insertion into C(sp3)–H bond.
Scheme 24: Rhodium porphyrin-based catalyst for enantioselective carbenoid insertion into benzylic C(sp3)–H bo...
Beilstein J. Org. Chem. 2016, 12, 796–804, doi:10.3762/bjoc.12.78
Graphical Abstract
Scheme 1: Pathway for transition-metal-catalyzed carbene insertion into C(sp3)–H bonds.
Scheme 2: Rh(II)-catalyzed site-selective and enantioselective C–H functionalization of methyl ether.
Scheme 3: Late-stage C–H functionalization with Rh(II)-catalyzed carbene C(sp3)–H insertion.
Scheme 4: The Rh(II)-catalyzed selective carbene insertion into benzylic C–H bonds.
Scheme 5: The structure–selectivity relationship.
Scheme 6: Rh-porphyrin complexes for catalytic intermolecular C–H insertions.
Scheme 7: Asymmetric intermolecular C(sp3)–H insertion with chiral Rh-porphyrin catalyst.
Figure 1: The structure of TpM catalysts.
Scheme 8: Ag-Tpx-catalyzed intermolecular C–H insertion between EDA and alkanes.
Scheme 9: Ag-Tpx-catalyzed C–H insertion of methane with EDA in scCO2.
Figure 2: Structure of TpM-type catalysts.
Scheme 10: Comparison of site-selectivities of C–H insertion in different reaction media.
Scheme 11: C(sp3)–H bond insertion catalyzed by trinuclear cluster Ag.
Scheme 12: Zn(II)-catalyzed C(sp3)–H bond insertion.
Beilstein J. Org. Chem. 2016, 12, 301–308, doi:10.3762/bjoc.12.32
Graphical Abstract
Scheme 1: Cascade 1,2-difunctionalization and cyclization to construct heterocycles.
Scheme 2: Cyclization of cyclohexane (2a) with substituted N-(2-methylallyl)benzamide (reaction conditions: 4...
Scheme 3: Cyclization of cycloalkanes with N-methyl-N-(2-methylallyl)benzamide (reaction conditions: 4a (0.2 ...
Scheme 4: Cyclization reaction of 6 with cyclohexane 2a (reaction conditions: 6 (0.2 mmol), cyclohexane 2a (2...
Scheme 5: Control experiments for the mechanism studies. a) Reaction with N-unprotected substrate 8a; b) reac...
Scheme 6: Proposed mechanism.
Beilstein J. Org. Chem. 2014, 10, 2594–2602, doi:10.3762/bjoc.10.272
Graphical Abstract
Figure 1: Pharmacologically active derivatives 1–4 containing the 1,4-benzoxazepine moiety or its analogue.
Scheme 1: Domino Knoevenagel–[1,5]-hydride shift cyclization reaction for the preparation of condensed 1,4-be...
Scheme 2: i) a) NaN3, CF3COOH, b) H2O, Δ (77%); ii) LiAlH4, dry THF, Δ (80%); iii) 11b, K2CO3, toluene, Δ (71...
Figure 2: Lowest-energy conformers of a) trans-(2S,15aS)-7a (>99.9%) with the replacement of the N-methyl gro...
Figure 3: Lowest-energy conformers of a) cis-(2R,15aS)-7a (99.4%) with the replacement of the N-methyl groups...
Figure 4: HPLC-ECD spectra of the first-eluting (black curve) and second-eluting (red curve) enantiomers of a...
Figure 5: Protective effect of compound 7a on hydrogen peroxide-induced neurotoxicity in SH-SY5Y cells. ##P <...
Figure 6: Protective effect of compound 7b on β-amyloid25–35-induced neurotoxicity in SH-SY5Y cells. ##P < 0....